Sarah M Bagley1, Marc R Larochelle2, Ziming Xuan3, Na Wang4, Aneesh Patel5, Dana Bernson6, Michael Silverstein7, Scott E Hadland8, Thomas Land9, Jeffrey H Samet10, Alexander Y Walley11. 1. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA. Electronic address: https://twitter.com/sbagley@bu.edu. 2. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA. 3. Department of Community Health Sciences, Boston University School of Public Health, Boston, MA. 4. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA. 5. Boston University School of Medicine, Boston, MA. 6. Massachusetts Department of Public Health, Boston, MA. 7. Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA. 8. Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA. 9. University of Massachusetts, Worcester, MA. 10. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA; Department of Community Health Sciences, Boston University School of Public Health, Boston, MA. 11. Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA; Grayken Center for Addiction, Boston Medical Center, Boston, MA; Massachusetts Department of Public Health, Boston, MA.
Abstract
STUDY OBJECTIVE: Nonfatal opioid overdose represents an opportunity to engage young adults into using medication for opioid use disorder. We seek to describe characteristics of young adults who experience nonfatal overdose and estimate rates of and time to medication for opioid use disorder for young adults relative to those aged 26 to 45 years. METHODS: We conducted a cohort study using retrospective administrative data of 15,281 individuals aged 18 to 45 years who survived an opioid-related overdose in Massachusetts between 2012 and 2014, using deidentified, individual-level, linked data sets from Massachusetts government agencies. We described patient characteristics stratified by age (18 to 21, 22 to 25, and 26 to 45 years) and evaluated multivariable Cox proportional hazards models to compare rates of medication for opioid use disorder receipt, controlling for age, sex, history of mental health disorders, and addiction treatment. RESULTS: Among 4,268 young adults in the year after nonfatal overdose, 28% (n=336/1,209) of those aged 18 to 21, 36% (n=1,097/3,059) of those aged 22 to 25 years, and 36% (n=3,916/11,013) of those aged 26 to 45 years received medication for opioid use disorder. For individuals aged 18 to 21 and 22 to 25 years, median time to buprenorphine treatment was 4 months (interquartile range 1.7 to 1.8 months); to methadone treatment, 4 months (interquartile range 2.8 to 2.9 months); and to naltrexone treatment, 1 month (interquartile range 1 to 1 month). Individuals aged 18 to 21 years were less likely (adjusted hazard ratio 0.60 [95% confidence interval 0.45 to 0.70]) to receive methadone than those aged 22 to 25 and 26 to 45 years. Individuals aged 18 to 21 years and those aged 22 to 25 years were more likely to receive naltrexone (adjusted hazard ratio 1.65 [95% confidence interval 1.36 to 2.00] and 1.41 [95% confidence interval 1.23 to 1.61], respectively) than those aged 26 to 45 years. CONCLUSION: One in 3 young adults received medication for opioid use disorder in the 12 months after surviving an overdose. Type of medication for opioid use disorder received appeared to be age associated. Future research should focus on how medication choice is made and how to optimize the emergency department for medication for opioid use disorder initiation after nonfatal overdose.
STUDY OBJECTIVE:Nonfatal opioid overdose represents an opportunity to engage young adults into using medication for opioid use disorder. We seek to describe characteristics of young adults who experience nonfatal overdose and estimate rates of and time to medication for opioid use disorder for young adults relative to those aged 26 to 45 years. METHODS: We conducted a cohort study using retrospective administrative data of 15,281 individuals aged 18 to 45 years who survived an opioid-related overdose in Massachusetts between 2012 and 2014, using deidentified, individual-level, linked data sets from Massachusetts government agencies. We described patient characteristics stratified by age (18 to 21, 22 to 25, and 26 to 45 years) and evaluated multivariable Cox proportional hazards models to compare rates of medication for opioid use disorder receipt, controlling for age, sex, history of mental health disorders, and addiction treatment. RESULTS: Among 4,268 young adults in the year after nonfatal overdose, 28% (n=336/1,209) of those aged 18 to 21, 36% (n=1,097/3,059) of those aged 22 to 25 years, and 36% (n=3,916/11,013) of those aged 26 to 45 years received medication for opioid use disorder. For individuals aged 18 to 21 and 22 to 25 years, median time to buprenorphine treatment was 4 months (interquartile range 1.7 to 1.8 months); to methadone treatment, 4 months (interquartile range 2.8 to 2.9 months); and to naltrexone treatment, 1 month (interquartile range 1 to 1 month). Individuals aged 18 to 21 years were less likely (adjusted hazard ratio 0.60 [95% confidence interval 0.45 to 0.70]) to receive methadone than those aged 22 to 25 and 26 to 45 years. Individuals aged 18 to 21 years and those aged 22 to 25 years were more likely to receive naltrexone (adjusted hazard ratio 1.65 [95% confidence interval 1.36 to 2.00] and 1.41 [95% confidence interval 1.23 to 1.61], respectively) than those aged 26 to 45 years. CONCLUSION: One in 3 young adults received medication for opioid use disorder in the 12 months after surviving an overdose. Type of medication for opioid use disorder received appeared to be age associated. Future research should focus on how medication choice is made and how to optimize the emergency department for medication for opioid use disorder initiation after nonfatal overdose.
Authors: Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin Journal: J Gen Intern Med Date: 2017-02-13 Impact factor: 5.128
Authors: Carla A Green; Nancy A Perrin; Shannon L Janoff; Cynthia I Campbell; Howard D Chilcoat; Paul M Coplan Journal: Pharmacoepidemiol Drug Saf Date: 2017-01-10 Impact factor: 2.890
Authors: Richard A Hansen; Mimi M Kim; Liping Song; Wanzhu Tu; Jingwei Wu; Michael D Murray Journal: Ann Pharmacother Date: 2009-03-03 Impact factor: 3.154
Authors: Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Joshua D Lee; John Rotrosen; Edward Nunes Journal: J Adolesc Health Date: 2020-08-29 Impact factor: 5.012
Authors: Sara J Becker; Kelli Scott; Sarah A Helseth; Kristin J Danko; Ethan M Balk; Ian J Saldanha; Gaelen P Adam; Dale W Steele Journal: J Subst Abuse Treat Date: 2021-05-29
Authors: Sarah M Bagley; Ziming Xuan; Michael Silverstein; Scott E Hadland; Alexander Y Walley Journal: Ann Emerg Med Date: 2020-04 Impact factor: 5.721
Authors: Samantha F Schoenberger; Tae Woo Park; Vanessa dellaBitta; Scott E Hadland; Sarah M Bagley Journal: J Gen Intern Med Date: 2021-06-07 Impact factor: 5.128
Authors: Vivian Y O Au; Tea Rosic; Nitika Sanger; Alannah Hillmer; Caroul Chawar; Andrew Worster; David C Marsh; Lehana Thabane; Zainab Samaan Journal: Harm Reduct J Date: 2021-07-08
Authors: Andrew A Herring; Aidan A Vosooghi; Joshua Luftig; Erik S Anderson; Xiwen Zhao; James Dziura; Kathryn F Hawk; Ryan P McCormack; Andrew Saxon; Gail D'Onofrio Journal: JAMA Netw Open Date: 2021-07-01